Loading...
Loading...
Contributors:
Dataset URI:
10.6084/m9.figshare.34786545.v2BackgroundSickle Cell Disease (SCD) is a hereditary condition affecting red blood cells and is most prevalent in sub-Saharan Africa, where the majority of global cases occur, including Tanzania. Although Hydroxyurea is effective in preventing disease crises, its cost-effectiveness compared to standard care remains unclear. This study evaluated the cost-effectiveness of hydroxyurea versus standard care in preventing sickle cell crises at Muhimbili National Hospital in Dar es Salaam, Tanzania.MethodologyA decision tree model was developed to assess the cost-effectiveness of hydroxyurea for preventing crises among patients with SCD attending the outpatient department at Muhimbili National Hospital. The analysis adopted a healthcare provider perspective, with costs reported in 2023 United States dollars (USD). A one-year time horizon corresponding to the 2023/24 fiscal year (1 July 2023 to 30 June 2024) was applied, using retrospective hospital data accessed between 14 April 2025 and 14 April 2026. Cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER), with effectiveness defined as the prevention of SCD crises. A willingness-to-pay threshold of up to three times Tanzania’s GDP per capita (USD 1,224) was used as a reference benchmark. Sensitivity analyses were conducted to assess parameter uncertainty and identify key drivers of model outcomes.ResultsCompared to standard care, the hydroxyurea strategy had an additional mean cost of USD 46,908.4 over one year. Crisis events were reduced by 99% in hydroxyurea compared to 63% in standard care. The incremental cost-effectiveness ratio (ICER) of hydroxyurea compared to standard care was USD 79.2 per crisis case prevented. Sensitivity analysis showed that hydroxyurea achieves nearly 100% probability of being below the willingness-to-pay thresholds.ConclusionThese findings indicate that the hydroxyurea strategy was associated with fewer documented SCD crises over the one-year study period than standard care at an incremental cost of USD 79.2 per crisis prevented. Therefore, hydroxyurea offers good value for money in preventing SCD crises.
Keyword(s):
Cost-effectiveness; sickle cell disease; sickle cell crisis; decision tree model; incremental cost-effectiveness ratio; Implementation science and evaluation.
MeSH Term(s):
Grants and Funding:
Associated Publication(s):
No Associated Publication Data Available
Supplementary Data:
No Supplementary Data Available
Related Dataset(s):
No Related Dataset Data Available
The National Library of Medicine (NLM) provides information about biomedical datasets. Inclusion on an NLM Web page does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: NLM Web Policies (nih.gov)